TENX
TENAX THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$1.90
+2.15%11
Insider buys (3m)
0
Insider sells (3m)
$4.9M
Net value (3m)
-84.3%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 17, 2026 | Doogan Declan · director | Purchase | 53,000 | $1.92 |
| Sep 15, 2026 | STAAB THOMAS R II · officer: Chief Financial Officer | Purchase | 5,675 | $1.94 |
| Sep 15, 2026 | Giordano Christopher Thomas · director, officer: CEO | Purchase | 6,000 | $1.88 |
| Sep 15, 2026 | Giordano Christopher Thomas · director, officer: CEO | Purchase | 4,850 | $1.82 |
| Sep 8, 2026 | ADAR1 Capital Management, LLC · 10 percent owner | Purchase | 900,000 | $1.78 |
| Sep 2, 2026 | ADAR1 Capital Management, LLC · 10 percent owner | Purchase | 403,571 | $1.79 |
| Sep 2, 2026 | ADAR1 Capital Management, LLC · 10 percent owner | Purchase | 179,058 | $1.80 |
| Sep 2, 2026 | ADAR1 Capital Management, LLC · 10 percent owner | Purchase | 187,704 | $1.80 |
| Aug 24, 2026 | ADAR1 Capital Management, LLC · 10 percent owner | Purchase | 716,369 | $1.77 |
| Aug 24, 2026 | ADAR1 Capital Management, LLC · 10 percent owner | Purchase | 202,124 | $1.78 |
| Aug 24, 2026 | ADAR1 Capital Management, LLC · 10 percent owner | Purchase | 107,374 | $1.75 |
| Jul 14, 2026 | Giordano Christopher Thomas · director, officer: CEO | M-Exempt | 219 | $3.55 |
| Jul 14, 2026 | Giordano Christopher Thomas · director, officer: CEO | M-Exempt | 8,500 | $5.94 |
| May 13, 2026 | STAAB THOMAS R II · officer: Chief Financial Officer | A-Award | 10,000 | $0.00 |
| May 13, 2026 | STAAB THOMAS R II · officer: Chief Financial Officer | A-Award | 450,000 | $12 |
| Feb 3, 2026 | MCGAULEY THOMAS · officer: Interim CFO | M-Exempt | 50,000 | $13 |
| Jan 13, 2026 | Rich Stuart · director, officer: Chief Medical Officer | A-Award | 250,000 | $13 |
| Jan 13, 2026 | Davidson Michael H. · director | A-Award | 30,000 | $13 |
| Jan 13, 2026 | Almenoff June Sherie · director | A-Award | 30,000 | $13 |
| Jan 13, 2026 | Doogan Declan · director | A-Award | 30,000 | $13 |
| Jan 13, 2026 | Hunter Robyn · director | A-Award | 30,000 | $13 |
| Jan 13, 2026 | PROEHL GERALD T · director | A-Award | 3,000 | $13 |
| Jan 13, 2026 | Giordano Christopher Thomas · director, officer: CEO | A-Award | 450,000 | $13 |
| Dec 10, 2025 | Rich Stuart · director, officer: Chief Medical Officer | Purchase | 2,500 | $10 |
| Dec 5, 2025 | Rich Stuart · director, officer: Chief Medical Officer | Purchase | 1,500 | $9.08 |
| Dec 5, 2025 | Rich Stuart · director, officer: Chief Medical Officer | Purchase | 1,000 | $9.01 |
| Dec 5, 2025 | Rich Stuart · director, officer: Chief Medical Officer | Purchase | 2,500 | $9.20 |
| Nov 20, 2025 | Giordano Christopher Thomas · director, officer: CEO | Purchase | 538 | $7.59 |
| Nov 20, 2025 | Giordano Christopher Thomas · director, officer: CEO | Purchase | 455 | $7.51 |
| Nov 20, 2025 | Giordano Christopher Thomas · director, officer: CEO | Purchase | 1,612 | $7.75 |
Institutional positioning
13F filings over the trailing two quarters
New 81Increased 69Reduced 19Sold out 10
| Filer | Action | Shares | Filed |
|---|---|---|---|
| FMR LLC | Increased | 3,942,373 | Aug 13, 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | New Position | 2,951,116 | May 15, 2026 |
| Vivo Capital, LLC | Increased | 2,500,000 | Aug 14, 2026 |
| JANUS HENDERSON GROUP PLC | Increased | 1,815,474 | May 18, 2026 |
| BlackRock, Inc. | Increased | 1,727,988 | Aug 7, 2026 |
| PERCEPTIVE ADVISORS LLC | Increased | 1,700,000 | Aug 14, 2026 |
| VR ADVISER, LLC | New Position | 1,675,262 | May 15, 2026 |
| PERCEPTIVE ADVISORS LLC | Increased | 1,447,782 | May 29, 2026 |
| Ikarian Capital, LLC | Increased | 1,177,200 | Aug 14, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 1,147,121 | Aug 13, 2026 |
| IKARIAN CAPITAL, LLC | Increased | 1,131,900 | May 15, 2026 |
| STONEPINE CAPITAL MANAGEMENT, LLC | Increased | 975,200 | May 14, 2026 |
| CITADEL ADVISORS LLC | Increased | 895,461 | Sep 2, 2026 |
| MILLENNIUM MANAGEMENT LLC | Increased | 876,230 | Aug 14, 2026 |
| Candriam S.C.A. | New Position | 749,588 | Aug 13, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 17, 2026